Physician profile
Stuart Lerner
NPI 1881647782
$17,943.54
in general payments reported to CMS, 2019-2025
43 companies · $4,706 in 2025
The $4,706 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $1,321 · 2021: $2,435 · 2022: $2,458 · 2023: $1,421 · 2024: $3,425 · 2025: $4,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,541 · Education: $10.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,540.79 |
| Education | $10.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,233.95 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $2,160.87 | 2020-2025 | |
| Lilly USA, LLC | $1,955.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,738.38 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $1,461.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $963.88 | 2024-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Amgen INC. | $521.30 | 2021-2025 | Krystexxa, Tavneos, Otezla |
| Pfizer INC. | $468.09 | 2019-2023 | |
| Janssen Biotech, INC. | $441.42 | 2025 | Tremfya |
| Amarin Pharma, INC. | $437.08 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $400.76 | 2024-2025 | |
| Allergan, INC. | $383.15 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $335.71 | 2024-2025 | Fanapt, Ponvory |
| Eisai INC. | $294.27 | 2021-2024 | |
| Abbott Laboratories | $264.82 | 2022-2024 | Proclaim |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Lerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.